Literature DB >> 17130882

Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls.

K K Nicodemus, A Luna, R Vakkalanka, T Goldberg, M Egan, R E Straub, D R Weinberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17130882     DOI： 10.1038/sj.mp.4001878

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  47 in total

1.  Predicting white matter integrity from multiple common genetic variants.

Authors:  Omid Kohannim; Neda Jahanshad; Meredith N Braskie; Jason L Stein; Ming-Chang Chiang; April H Reese; Derrek P Hibar; Arthur W Toga; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; Nicholas G Martin; Margaret J Wright; Paul M Thompson
Journal:  Neuropsychopharmacology       Date:  2012-04-18       Impact factor: 7.853

2.  Finding a druggable target for schizophrenia.

Authors:  Beatriz Rico
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

3.  Genetic association of ErbB4 and human cortical GABA levels in vivo.

Authors:  Stefano Marenco; Matthew Geramita; Jan Willem van der Veen; Alan S Barnett; Bhaskar Kolachana; Jun Shen; Daniel R Weinberger; Amanda J Law
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

4.  ErbB4 is a suppressor of long-term potentiation in the adult hippocampus.

Authors:  Graham M Pitcher; Simon Beggs; Ran-Sook Woo; Lin Mei; Michael W Salter
Journal:  Neuroreport       Date:  2008-01-22       Impact factor: 1.837

5.  Specific regulation of NRG1 isoform expression by neuronal activity.

Authors:  Xihui Liu; Ryan Bates; Dong-Min Yin; Chengyong Shen; Fay Wang; Nan Su; Sergei A Kirov; Yuling Luo; Jian-Zhi Wang; Wen-Cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2011-06-08       Impact factor: 6.167

Review 6.  Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.

Authors:  Colm M P O'Tuathaigh; Paula M Moran; Xuechu C Zhen; John L Waddington
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

Review 7.  Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome.

Authors:  Anamika Banerjee; Mathew L Macdonald; Karin E Borgmann-Winter; Chang-Gyu Hahn
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 8.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 9.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

Review 10.  Imaging genetics of structural brain connectivity and neural integrity markers.

Authors:  Stefano Marenco; Eugenia Radulescu
Journal:  Neuroimage       Date:  2009-11-22       Impact factor: 6.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.